Cromos Pharma, where the patients are

Drug Sponsors

Grifols to acquire Novartis blood transfusion diagnostics unit for $1.675 billion

Monday, November 11, 2013 04:42 PM

Novartis announced a definitive agreement to divest its blood transfusion diagnostics unit to Grifols for $1.675 billion. This transaction, requiring customary regulatory approvals, is expected to be completed in the first half of 2014.

More... »

CRF Health eCOA webinar series

Shire to acquire ViroPharma for $4.2 billion

Monday, November 11, 2013 02:55 PM

Shire and ViroPharma have entered a merger agreement in which Shire will acquire all the outstanding shares of ViroPharma in a cash deal valued at a total of $4.2 billion.

More... »


Salix Pharmaceuticals to acquire Santarus

Friday, November 8, 2013 12:11 PM

Salix Pharmaceuticals will acquire Santarus, a specialty biopharmaceutical company, in an all-cash transaction valued at approximately $2.6 billion. 

More... »

Shire updates reorganization program, Basingstoke site consolidated

Friday, November 8, 2013 12:10 PM

Shire Pharmaceuticals has updated its “One Shire” program and has initiated an employee consultation process at its site in Basingstoke.

More... »

Ariad reduces U.S. workforce by 40%

Friday, November 8, 2013 12:09 PM

Ariad Pharmaceuticals, headquartered in Cambridge, Mass., and Lausanne, Switzerland, is cutting approximately 40% of its staff positions in the U.S. following its decision to temporarily suspend the marketing and commercial distribution of Iclusig (ponatinib) in the U.S.

More... »

Novartis proposes to close U.K. site, 371 jobs may be cut

Wednesday, November 6, 2013 12:57 PM

Novartis U.K. will initiate consultation on proposals to close its Horsham site in West Sussex, affecting up to 371 employees, but subject to an employee consultation process and final U.K. board approval.

More... »

Endo to acquire Paladin Labs

Wednesday, November 6, 2013 12:48 PM

Endo Health Solutions has reached a definitive agreement to acquire Paladin Labs, a Canada-based specialty pharmaceutical company, in a stock and cash transaction valued at approximately $1.6 billion, of which approximately 98% will be paid in stock. The acquisition accelerates Endo's strategic transformation to a global specialty healthcare company and creates a platform for future growth in North America and internationally. Each share of Endo and Paladin Labs will be acquired by a newly-formed Irish holding company (New Endo). At $77 per Paladin Labs share, the transaction represents a 20% premium to Paladin Labs' share price on Nov. 4.

More... »

Pfizer responds to U.K. pharma pricing deal

Wednesday, November 6, 2013 12:43 PM

Pfizer released a statement calling the new Pharmaceutical Price Regulation Scheme (PPRS), agreed to by the U.K. government and industry, a missed opportunity for British patients, the U.K. economy and industry.

More... »

Johnson & Johnson, Janssen Pharmaceuticals, Scios finalize Risperdal settlements, will pay $2 billion

Monday, November 4, 2013 02:18 PM

Johnson & Johnson and its subsidiaries, Janssen Pharmaceuticals and Scios have finalized previously disclosed settlement agreements with the U.S. Department of Justice (DOJ) and 45 states resolving federal investigations and state Medicaid claims related to past promotional practices of Risperdal (risperidone) from 1999 through 2005, and other matters. The resolution includes total settlement amounts of approximately $2 billion to the federal government and state Medicaid programs, an amount previously accrued, and no additional charge to the company’s earnings will be recorded in connection with this settlement.

More... »

Teva announces departure of president and CEO Jeremy Levin

Monday, November 4, 2013 01:38 PM

Teva Pharmaceutical Industries said its board of directors has agreed with Dr. Jeremy Levin’s decision to step down as president and chief executive officer. The board has named Eyal Desheh, Teva's executive vice president and chief financial officer, to fill the role of president and chief executive officer on an interim basis, effective immediately, and it has formed a committee to search for a permanent successor.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs